drugset / Trial / NCT05616013
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
RandomizedFactorialDouble-blindTreatment
Summary
A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women
Timeline
- Start
- 2022-11-16
- Primary completion
- 2024-05-16
- Completion
- 2025-06-14
Publications
- Heymsfield SB, Aronne LJ, Montgomery P, Klickstein LB, Coleman LA, Dole K, Mindeholm L, Spruill S, Li X, Attie KM; BELIEVE trial investigators. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nat Med. 2026 Mar;32(3):869-882. doi: 10.1038/s41591-026-04204-0. Epub 2026 Mar 2.
- Moon S, Choi JW, Park JH, Kim DS, Ahn Y, Kim Y, Kong SH, Oh CM. Association of Appendicular Skeletal Muscle Mass Index and Insulin Resistance With Mortality in Multi-Nationwide Cohorts. J Cachexia Sarcopenia Muscle. 2025 Apr;16(2):e13811. doi: 10.1002/jcsm.13811.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bimagrumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Bimagrumab | Monoclonal antibody | 30 mg/kg | Intravenous |
| Subject | Semaglutide | Peptide | 1 mg | Subcutaneous |
| Subject | Semaglutide | Peptide | 2.4 mg | Subcutaneous |